Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase

Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediate...

Full description

Saved in:
Bibliographic Details
Main Authors MIRZADEGAN TARANEH, EPPERSON MATTHEW T, LANDRY-BAYLE ADRIENNE M, ECCLES WENDY, EDWARDS JAMES P, MCCLURE KELLY J, KEARNEY AARON M, BACANI GENESIS M, LEE-DUTRA ALICE, BEMBENEK SCOTT D, SANTILLAN ALEJANDRO JR, GOMEZ LAURENT, GRICE CHERYL A
Format Patent
LanguageChinese
English
Published 08.12.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
Bibliography:Application Number: CN200880123541